Compare Monster Beverage Corp (MNST) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs Repligen Corporation Common Stock — how do they compare? Monster Beverage Corp trades at $44.83 (market cap $86.63B), while Repligen Corporation Common Stock trades at $178.2 (market cap $11.31B). The key difference: Monster Beverage Corp is far larger — about 7.7× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Monster Beverage Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Monster Beverage Corp for 72 Days and Repligen Corporation Common Stock for 0 Days on average.
| MNST | RGEN | |
|---|---|---|
Market Cap | $86.63B | $11.31B |
Volume | 11,197,663 | 1,216,919 |
Sector | Consumer Staples | Health |
52-Week High | $49.97 | $194.57 |
52-Week Low | $33.16 | $102.87 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $84.92B | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $43.31, down 1.03% today, with a bullish technical signal supported by moving averages. The company demonstrates strong fundamentals with 2025 revenue of $8.29B, net income of $1.91B (23.08% margin), and consistent earnings beats in recent quarters. Recent news highlights international expansion success and a debt-free balance sheet as key strengths, while a 1:2 stock split occurred in August 2026.
MNST presents a compelling growth story with robust profitability and international momentum, though elevated valuation multiples (P/E 40.1) warrant caution. Analyst consensus remains positive with a $98.22 price target (52.27% buy ratings), but regulatory challenges in key markets like India and competitive pressures represent ongoing risks for investors.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
